High 5hmC predicts worse OS - Ep 2.6

In this episode of the HemaSphere podcast, host Charles de Bock discusses the latest research on myelodysplastic syndrome (MDS) with Dr Francesca Tiso and Dr Florentien in 't Hout from Radboud University Medical Center, co-authors of a recent paper published in HemaSphere. The conversation covers the clinical presentation of MDS, treatment options, and the significance of genetic mutations. Delve into their study on the prognostic value of hydroxymethylation levels in patients treated with azacitidine, highlighting the challenges of risk stratification and patient recruitment. They also discuss future research directions and the comparative efficacy of azacitidine and decitabine.

“High 5hmC predicts worse OS” is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube.

Listen and enjoy casual, insightful discussions about #hematology research.

You can find the referenced article, in full and open access, here on the HemaSphere website.